November 22, 2023 — The first clinical trial to challenge the routine implantation of a defibrillator in myocardial infarction survivors with heart failure has enrolled its first patient.

November 21, 2023 — BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today presented additional Phase 3 data from ATTRibute-CM, its study of acoramidis in transthyretin amyloid cardiomyopathy, or ATTR-CM, at the American Heart Association (AHA

November 21, 2023 — Heuron, a medical AI (artificial intelligence) imaging software solution company, under the leadership of CEO Dr. Donghoon Shin, is scheduled to take part

November 20, 2023 — In the U.S., nearly 10,000 children and adolescents have developed a condition called multisystem inflammatory syndrome, or MIS-C, following 

November 20, 2023 — Abbott announced new late-breaking data that show advanced heart failure patients living with its HeartMate 3 heart pump who didn't receive aspirin as part of th

November 20, 2023 — Student engineers from the University of Bath are on top of the world after winning an international competition to design an artificial heart. 

Team Bath Heart took top prize at the grand final of the first-ever Heart Hackathon, which was held in Texas at the end of October. 

Six members of the team presented their device to global experts in artificial heart technologies, competing against teams from Australia, the United States, Sweden, New Zealand, Romania and Egypt. 

November 20, 2023 — Medtronic plc, a global leader in healthcare technology, announced that the United States Food and Drug Administration (FDA) has approved the Symplicity Spyral renal denervation (RDN) system, also known as the Symplicity blood pressure procedure, for the treatment of hypertension. With this approval, Medtronic will immediately begin commercialization.

Subscribe Now